Kiniksa Pharmaceuticals International, plc (KNSA) News
Track canonical SquawkNews coverage tagged to KNSA, Kiniksa Pharmaceuticals International, plc. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 9 indexed stories across 3 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
KNSA Reiterate Buy, raise PT to $98 (from $64) after results @ Canaccord
KNSA Reiterate Buy, raise PT to $98 (from $64) after results @ Canaccord
EARNINGS | Jul 29, 2026, 12:46 PM UTC
H
KNSA Raised to $100 PT at Citi
Citi raises KNSA price target
EQUITY | Jul 29, 2026, 10:45 AM UTC
H
Crude Oil Down Over 5%; Boeing Shares Rise After Q2 Results
U.S. stocks traded mostly higher midway through trading, with the Dow Jones index gaining more than 1% on Tuesday. The Dow traded up 1.25% to 52,860.91 while the NASDAQ slipped 0.01% to 24,928.70. The S&P 500 also rose,
MACRO | Jul 28, 2026, 04:28 PM UTC
H
Sherwin-Williams Posts Upbeat Q2 Earnings, Joins Itron, Armstrong World And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were mixed, with the Dow Jones index gaining around 300 points on Tuesday. Shares of Sherwin-Williams Co (NYSE: SHW ) rose sharply after the company reported better-than-expected second-quarter financial resu
EARNINGS | Jul 28, 2026, 02:05 PM UTC
L
Kiniksa raises FY26 revenue view to $980M-$995M from $930M-$945M
Consensus $940.13M. The...
EARNINGS | Jul 28, 2026, 11:46 AM UTC
L
Kiniksa reports Q2 EPS 30c, consensus 28c
Reports Q2 revenue...
EARNINGS | Jul 28, 2026, 11:45 AM UTC
L
Kiniksa Pharmaceuticals Raises FY2026 Sales Guidance from $930.000M-$945.000M to $980.000M-$995.000M vs $940.106M Est
Kiniksa Pharmaceuticals (NASDAQ: KNSA ) raises FY2026 sales outlook from $930.000 million-$945.000 million to $980.000 million-$995.000 million vs $940.106 million estimate.
EARNINGS | Jul 28, 2026, 11:30 AM UTC
L
KNSA Kiniksa Pharmaceuticals RESULTS: Q2, Q2 operating expenses $216.406M, Q2 Net Income $25.432M, Q2 pretax profit $31.145M, Kiniksa Pharma
KNSA Kiniksa Pharmaceuticals RESULTS: Q2, Q2 operating expenses $216.406M, Q2 Net Income $25.432M, Q2 pretax profit $31.145M, Kiniksa Pharmaceuticals Earnings Notes:, - Kiniksa Pharmaceuticals Q2 product REV $243.6M
EARNINGS | Jul 28, 2026, 11:30 AM UTC
M
Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $72
Wedbush analyst David Nierengarten maintains Kiniksa Pharmaceuticals (NASDAQ: KNSA ) with a Outperform and raises the price target from $59 to $72.
EQUITY | Jun 29, 2026, 01:32 PM UTC